Summary by Moomoo AI
MICROCHUN MEDICAL SCIENCES CO., LTD. (MICROCHUN MEDICAL) ANNOUNCES ITS FIRST QUARTER FINANCIAL REPORT FOR 2024, WHICH OWNS APPROXIMATELY 40.32% OF ITS SHAREHOLDING OF APPROXIMATELY 40.32% OF SHANGHAI MICROCHUN HEART MEDICAL TECHNOLOGY (CARDIAC MEDICAL TECHNOLOGY). The report showed that Cardiac Medical Technology's first-quarter operating income reached RMB358,081,405.15, up 25.38% year-on-year, and net profit attributable to shareholders of listed companies was RMB184,296,095.55, an increase of 47.62% year-on-year. R&D investment totaled RMB 47,137,794.16, accounting for 13.16% of operating income, a decrease of 8.14 percentage points from the same period last year. During the reporting period, Cardiac Medical Technology's total assets and shareholders' equity of listed companies increased by 6.55% and 5.17%, respectively. The financial statements for the quarter are unaudited. Micro-Chung Medical Sciences Limited made this announcement to investors via the exchange website on April 26, 2024 in compliance with the disclosure requirements of section 13.10B of the Listing Rules.